drugset / Trial / NCT07441174
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
Phase 1/2
Recruiting
92 enrolled
InxMed (Shanghai) Co., Ltd.
InxMed (Shenzhen) Co.,Ltd. · collabRanok Therapuetics Co. Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, Phase Ib/II clinical study. The study includes Phase Ib-Dose Exploration Stage and Phase II - Efficacy Exploration and Determination Stage.
Timeline
- Start
- 2026-02-28
- Primary completion
- 2031-02-28
- Completion
- 2031-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ifebemtinib | Small molecule | 100 mg | Oral |
| Subject | RNK08954 | Unknown | 1000 mg | Oral |
| Subject | RNK08954 | Unknown | 1200 mg | Oral |